|
ANTIPAF
Angiotensin II antagonist In Paroxysmal Atrial Fibrillation
Ongoing trial
 |
Author(s) |
Goette A, Breithardt G, Fetsch T, Hanrath P, Klein HU, Lehmacher W, Steinbeck G, Meinertz T |
 |
Title(s) |
Angiotensin II antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial. Rationale and study design |
|
Reference(s) |
Clin Drug Invest 2007;27:697–705 |
|
Disease |
Atrial fibrillation |
|
Purpose |
To investigate if blockade of angiotensin II type 1 receptors with olmesartan suppresses paroxysmal atrial fibrillation episodes |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Aim 12 months |
|
Patients |
Aim 422 patients, aged ≥ 18 years, with documented paroxysmal atrial fibrillation, stratified by use of beta-blockers |
|
Treatment regimen |
Olmesartan medoxomil, 40 mg/day, or placebo |
|
Results |
Not yet available |
|
|
|
